Chronic Myeloid Leukemia
📧 Sign up to get email alerts when something new happens for Chronic Myeloid Leukemia.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-07EMA Authorised: Scemblix (asciminib hydrochloride) — Novartis Europharm Limited
EMA authorised Scemblix (asciminib hydrochloride) for chronic myeloid leukemia with BCR-ABL positive status.
-
EMA approval · 2026-07-20EMA Authorised: Scemblix (asciminib hydrochloride) — Novartis Europharm Limited
Scemblix (asciminib hydrochloride) has been authorised in the EU for chronic myeloid leukemia positive for BCR-ABL, with orphan designation.
-
FDA approval · 2026-04-14FDA Approved: DANZITEN — Supplemental Application (Azurity Pharmaceuticals, Inc.)
The FDA approved a supplemental application for Danziten (nilotinib) submitted by Azurity Pharmaceuticals, Inc. The supplement adds to the e…
-
EMA approval · 2026-04-09EMA Authorised: Iclusig (ponatinib) — Incyte Biosciences Distribution B.V.
The European Medicines Agency authorised Iclusig (ponatinib) from Incyte Biosciences Distribution B.V. for certain leukemias, including chro…
-
FDA approval · 2026-04-06FDA Approved: IMATINIB MESYLATE — Supplemental Application (BluePoint Laboratories)
FDA approved BluePoint Laboratories' supplemental application for Imatinib Mesylate (ANDA 212773), approving a generic version of the cancer…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-03-06EMA Authorised: Sprycel (dasatinib) — Bristol-Myers Squibb Pharma EEIG
The EMA authorised Sprycel (dasatinib). It covers chronic myeloid leukemia (BCR-ABL positive) and precursor cell lymphoblastic leukemia-lymp…
-
EMA approval · 2026-03-05EMA Authorised: Imatinib Teva (imatinib) — Teva B.V.
EMA authorised Imatinib Teva (imatinib) for multiple indications including chronic myeloid leukemia, precursor cell lymphoblastic leukemia-l…
-
FDA approval · 2026-03-02FDA Approved: BOSULIF — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
The FDA approved a supplemental application for Bosulif (bosutinib) from Pfizer Laboratories Div Pfizer Inc.
-
FDA approval · 2026-03-02FDA Approved: BOSULIF — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for BOSULIF (bosutinib) submitted by Pfizer Laboratories Div Pfizer Inc. The document does not speci…
-
EMA approval · 2026-02-05EMA Authorised: Dasatinib Accord Healthcare (Dasatinib monohydrate) — Accord Healthcare S.L.U.
EMA authorised Accord Healthcare's dasatinib monohydrate product (Dasatinib Accord Healthcare) for precursor B-cell lymphoblastic leukemia/l…
-
EMA approval · 2026-01-12EMA Authorised: Bosulif (bosutinib (as monohydrate)) — Pfizer Europe MA EEIG
The European Medicines Agency authorised Bosulif (bosutinib) for treatment of chronic myeloid leukemia in the European Union, with Pfizer Eu…
-
EMA approval · 2025-12-19EMA Authorised: Tasigna (nilotinib) — Novartis Europharm Limited
The European Medicines Agency authorised Tasigna (nilotinib) for chronic myeloid leukemia (BCR-ABL positive); the marketing authorisation ho…
-
FDA approval · 2025-12-15FDA Approved: NILOTINIB — Original Application (Torrent Pharmaceuticals Limited)
The FDA approved Torrent Pharmaceuticals Limited's original application for nilotinib, a generic version of the cancer drug Tasigna, for tre…
-
EMA approval · 2025-12-08EMA Authorised: Scemblix (asciminib hydrochloride) — Novartis Europharm Limited
The European Medicines Agency authorised Scemblix (asciminib hydrochloride) for chronic myeloid leukemia (BCR-ABL positive) and granted orph…
-
FDA approval · 2025-11-25FDA Approved: SCEMBLIX — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for SCEMBLIX (asciminib) submitted by Novartis Pharmaceuticals Corporation.
-
FDA approval · 2025-11-19FDA Approved: NILOTINIB — Original Application (Dr. Reddy's Laboratories Inc)
FDA approved Dr. Reddy's Laboratories' generic nilotinib under an Original Application (ANDA). It is indicated for chronic myeloid leukemia …
-
FDA approval · 2025-11-19FDA Approved: NILOTINIB — Original Application (AvKARE)
FDA approved AvKARE's nilotinib original application, authorizing a generic version of nilotinib for leukemia indications.
-
FDA approval · 2025-11-19FDA Approved: NILOTINIB — Original Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' original application for a generic nilotinib product. The generic is intended to treat certain Philadel…
-
FDA approval · 2025-11-14FDA Approved: DANZITEN — Supplemental Application (Azurity Pharmaceuticals, Inc.)
FDA action on a supplemental application for DANZITEN (nilotinib) from Azurity Pharmaceuticals, Inc.
-
EMA approval · 2025-11-12EMA Authorised: Glivec (imatinib) — Novartis Europharm Limited
The European Medicines Agency authorised Glivec (imatinib) for multiple indications, including precursor cell lymphoblastic leukemia-lymphom…
-
FDA approval · 2025-11-06FDA Approved: DASATINIB — Original Application (Alembic Pharmaceuticals Limited)
FDA approved a generic version of dasatinib (DASATINIB) from Alembic Pharmaceuticals Limited under an Original Application. The approval mak…
-
FDA approval · 2025-10-02FDA Approved: SCEMBLIX — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for SCEMBLIX (asciminib) submitted by Novartis, resulting in changes to the drug's labeling.
-
FDA approval · 2025-09-30FDA Approved: DASATINIB — Supplemental Application (Dr.Reddys Laboratories Inc)
The FDA has approved a supplemental application for dasatinib from Dr. Reddy's Laboratories Inc, authorizing an update to the approval of th…
-
EMA approval · 2025-09-11EMA Authorised: Nilotinib Accord (nilotinib) — Accord Healthcare S.L.U.
Accord Healthcare S.L.U. has been authorised to market Nilotinib Accord for chronic myeloid leukemia that is BCR-ABL positive.
-
FDA approval · 2025-08-28FDA Approved: DASATINIB — Supplemental Application (Apotex Corp.)
The FDA approved Apotex Corp.'s supplemental application for dasatinib (DASATINIB).